Nestor Esnaola, MD
Surgical Oncology · Philadelphia, PANPI 1013021666
Payments from drug & device makers
What this record shows
This record is dominated by education: $14,000 of the $16,773 with a category attached, or 83.5%. Intuitive Surgical accounts for 98.7% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2021 at $16,561 and has fallen 98.9% since, to $178 in 2024. Among surgical oncology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $399.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$17K
- Baxter Healthcare$144
- TELA Bio, Inc.$34
- Johnson & Johnson$33
Across 3 payments — averaging $11,329 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$34K
What the payments were for
- Travel & lodging$2,07812%
- Food & beverage$6944%
- Education$14,00083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 38 | $16,561 |
| Baxter Healthcare | 1 | $144 |
| TELA Bio, Inc. | 2 | $34 |
| Johnson & Johnson | 1 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$15,643
- PerClot$144
How this compares
$16,773 in reported general payments places this provider in the 95th percentile of 78 surgical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 30 | $40,851 |
Paid to pharmacies, not to this prescriber.
Other surgical oncology in Philadelphia
- Richard BleicherPhiladelphia$53K
- Andrea PorpigliaPhiladelphia$11K
- Mark EtheringtonPhiladelphia$6K
- Anthony VillanoPhiladelphia$4K
- Stephanie GrecoPhiladelphia$3K
- James SunPhiladelphia$3K
- John RidgePhiladelphia$3K
- Steven StandifordPhiladelphia$487
- Alliric WillisPhiladelphia$254
- Jennifer ZhangPhiladelphia$200
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.